This site uses cookies to bring you the best experience. Find out more
Skip to main content


TOSP agrees to sale of development site to Lawrence J. Ellison Institute for Transformative Medicine

The Oxford Science Park agrees to sale of development site to the

Lawrence J. Ellison Institute for Transformative Medicine

US research organisation creates new campus to build collaborations across the Oxford life science ecosystem

Oxford, UK, July 18 2022 – Leading US-based research organisation, the Lawrence J. Ellison Institute for Transformative Medicine, is significantly expanding its commitment to Oxford by establishing a major presence at The Oxford Science Park (TOSP), one of Europe’s leading locations for science and technology companies.

To facilitate the development of the Ellison Institute’s new Oxford campus, TOSP has agreed to sell a 150-year lease on a 3.5 acre site in the Park. This will connect directly with the adjacent 5.9-acre Littlemore House site that the Ellison Institute acquired in December 2021, creating a major presence in Oxford. The Ellison Institute’s Oxford campus will provide a permanent home to research laboratories, a patient clinic, offices, and collaborative spaces supporting Ellison Institute projects, including the Global Health Security Consortium’s work on pandemic preparedness.

The development will enable the Ellison Institute to collaborate extensively with companies and organisations across the Park, as well as the wider Oxford innovation ecosystem. The new location also enables the Ellison Institute to expand its existing partnership with Oxford Nanopore Technologies, one of the major international companies based at the Park.

Rory Maw, CEO of The Oxford Science Park, said, ‘We’re delighted to welcome the Ellison Institute to the Park and look forward to working with the team to help deliver their vision for the new Oxford campus. This commitment will reinforce the ground-breaking research and development already taking place on the Park, delivering benefits and opportunities for our occupiers and the wider Oxford innovation ecosystem.’

Dinah Rose QC, President of Magdalen College, said, “Following closely on from our strategic partnership with GIC, the Singapore sovereign wealth fund, this is an exciting next step in the evolution of the Park. We look forward to developing a close long-term relationship with the Ellison Institute and to enhancing further Oxford’s enormous contribution to addressing global health challenges.’

‘We look forward to continuing the development of our Oxford presence and partnerships,’ said Dr David Agus, founding director and CEO of the Ellison Institute. ‘These acquisitions give us greater capacity to undertake critical biomedical research as well as the educational initiatives of the Institute in collaboration with Oxford University.’


For more information, please contact:

The Oxford Science Park                                                         

Emma Palmer Foster, Strategic Communications Consultant

T: +44 (0)7880 787185

Notes to editors

About the Lawrence J. Ellison Institute for Transformative Medicine

The Lawrence J. Ellison Institute leverages technology, sparks innovation, and drives interdisciplinary, evidence-based research to reimagine and redefine cancer treatment, enhance health, and transform lives. Under the leadership of Dr. David Agus, the Institute’s goal is to redefine medicine by bringing together a diverse set of clinicians, scientists, and thought leaders to collaborate and drive innovation in cancer treatment, infectious disease, and overall human health.

Building community and forging partnerships are at the heart of what the Institute does to improve patient health. Through a multifaceted, collaborative approach, the Institute partners with research organizations and technology companies to accelerate medical innovation. The Institute offers multifaceted programs, including a cancer clinic, cross-disciplinary research laboratories, a health policy think-tank, and community outreach and educational programs. There is more information at

About The Oxford Science Park

The Oxford Science Park is majority owned by Magdalen College, Oxford, upholding its research heritage and its strategy to support discovery, innovation and entrepreneurship. Providing an influential science and technology environment, the Park has ambitious plans to create an additional 500,000+ sq. ft. of office and laboratory space over the next 3 years alongside its strategic partner GIC. This additional capacity will support the growth of businesses already based on the Park, providing flexible workspace accommodation, and enabling new companies to enjoy the Park’s exceptional environment and collegiate and collaborative ethos.

TOSP is home to 2,700 people and more than 130 businesses. These range from start-ups based in the Magdalen Centre innovation hub to major international companies and include Blue Earth Diagnostics, MiroBio, OrganOx, OxSonics Therapeutics, Oxford Nanopore Technologies, OXGENE, ProImmune, Oxford Science Enterprises, Evox Therapeutics, Exscientia and Intuitive Surgical.

The Oxford Science Park is located approximately four miles south-east of Oxford city centre, just off the City’s southern ring road. It has easy access to the M40 and A34, as well as to Heathrow Airport and mainline train services. For further information, please visit: or follow us on twitter @OxfordSciencePK and LinkedIn

Read other news articles

Get In Touch

Share this

The Daubeny Project

Imaginative design, inspiring spaces.